Clinical Trial Update: 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis [Phase 3]

View source ↗

Summary

Phase 3 trial update reports 16-week efficacy and 5-year long-term efficacy, safety, and tolerability of secukinumab in active ankylosing spondylitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Anklyosing Spondylitis | Phase 3 | Status: COMPLETED | Results posted: 2019-10-30